The New York University Cancer Institute (NYUCI) is seeking renewal of its CCSG funding for its 33rd year as an NCI-designated cancer center. Importantly the NYUCI seeks to reacquire comprehensive status given our long track record of accomplishments in population science and our expanded efforts in this area. Major progress has been made in all areas since the appointment of Dr. William L. Carroll as the new Director of NYUCI in 2008. Forty-six new faculty members have been recruited, membership has grown from 172 to 203, and funding has increased to $107.5M, a 35% increase. NCI funding is $23M and other NIH funding is $54M, 8% and 34% increases respectively. NYUCI facilities, under the direct control of Dr. Carroll, have increased by 38% with the opening of an additional ambulatory facility and the planned opening of the Breast Screening Center in spring 2012. Finally, patient volume (in visits) has increased by 35% since 2006 with a total of 170,335 visits at the Clinical Cancer Center, Bellevue Cancer Center, Woodhull Medical Center, Columbus Oncology and the Hassenfeld Children's Center combined in 2011. Accrual to therapeutic studies has grown by 45%, from 13% to almost 20%. Importantly, 68.6% of all accruals are to investigator-initiated studies. In the current application two population-based programs are presented, Environmental and Molecular Carcinogenesis and a new program in Epidemiology and Cancer Control. Dr. Richard Hayes was recruited from the NCI to be Associate Director of Population Sciences and has greatly expanded our efforts in this area. In addition programs in Stem Cell Biology, Cancer Immunology, Growth Control, Melanoma, GU and Breast Cancer are presented. Research in all programs is highly collaborative as demonstrated by increase in collaborative publications from 25% to 38% average across the Research Programs today and the submission of four SPORE applications and one PPG in the past 3 years. Twelve Shared Resources are supported by CCSG funds including three new Shared Resources, RNAi, Biorepository Center and Biomedical Informatics. The Cancer Center Support Grant (CCSG) builds on the many NYU institutional strengths including its presence in the metropolitan campus with a highly diverse faculty, staff and patient population. The NYUCI and CCSG application continues to be a priority of the President of NYU, the Dean and CEO of the NYU-Langone Medical Center, the Boards of both the Hospital and Institute and Community leadership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016087-35S1
Application #
8994822
Study Section
Subcommittee G - Education (NCI)
Program Officer
Roberson, Sonya
Project Start
1996-12-01
Project End
2018-02-28
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
35
Fiscal Year
2015
Total Cost
$611,572
Indirect Cost
$220,542
Name
New York University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Wang, Shiyang; Liechty, Benjamin; Patel, Seema et al. (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183-190
Nancy, Patrice; Siewiera, Johan; Rizzuto, Gabrielle et al. (2018) H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition. J Clin Invest 128:233-247
Schulfer, Anjelique F; Battaglia, Thomas; Alvarez, Yelina et al. (2018) Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 3:234-242
Ge, Wenzhen; Clendenen, Tess V; Afanasyeva, Yelena et al. (2018) Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. Int J Cancer 142:2215-2226
Ruggles, Kelly V; Wang, Jincheng; Volkova, Angelina et al. (2018) Changes in the Gut Microbiota of Urban Subjects during an Immersion in the Traditional Diet and Lifestyle of a Rainforest Village. mSphere 3:
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Gupta, Ankit; Xu, Jing; Lee, Shirley et al. (2018) Facile target validation in an animal model with intracellularly expressed monobodies. Nat Chem Biol 14:895-900
Marié, Isabelle J; Chang, Hao-Ming; Levy, David E (2018) HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies. J Exp Med 215:3194-3212
Evensen, Nikki A; Madhusoodhan, P Pallavi; Meyer, Julia et al. (2018) MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica 103:830-839
Lee, Hyun-Wook; Park, Sung-Hyun; Weng, Mao-Wen et al. (2018) E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. Proc Natl Acad Sci U S A 115:E1560-E1569

Showing the most recent 10 out of 1170 publications